GPD1 Genotype

Most of the genes that shape your health risk show up on standard panels. GPD1 (glycerol-3-phosphate dehydrogenase 1) and its close relative GPD1L are not among them, but the variants they carry can quietly drive two very different problems: severe fat buildup in the liver during infancy, and inherited heart rhythm disorders that can cause sudden cardiac arrest in otherwise healthy people.

This is a one-time genetic test that reads the DNA sequence at the GPD1 locus. The result tells you whether you carry rare variants that have been linked, in published human research, to metabolic liver disease or to electrical instability in the heart. Because the variants involved are uncommon and high-impact, this is a Tier 3 marker: useful in specific clinical contexts, but not a routine screen.

What These Genes Actually Do

GPD1 and GPD1L are two distinct but related genes. GPD1 codes for an enzyme that helps your body shuttle building blocks between fat metabolism and energy production. It plays a particularly important role in the liver, where it influences how triglycerides (the main form of fat stored in the body) are processed. GPD1L is a separate, paralogous gene whose protein sits inside heart muscle cells, where it interacts with the sodium channels that fire each heartbeat.

When GPD1 function is lost, the liver loses a key step in fat handling. When GPD1L function is reduced, heart muscle cells produce less sodium current, which can destabilize the electrical signal that triggers each contraction. Both effects are clinically meaningful, but they involve different variants in different genes and different organ systems.

Liver Disease in Infancy

The clearest human evidence for GPD1 variants comes from infants with severe metabolic liver disease. The first published report linking biallelic GPD1 mutations to human disease came in 2012, when Basel-Vanagaite and colleagues described 10 patients from four consanguineous Israeli Arab families with transient infantile hypertriglyceridemia, fatty liver, and hepatic fibrosis. A later case, reported by Joshi and colleagues in 2014, identified the first compound heterozygous mutation: a child with massive liver enlargement, fat accumulation in the liver (steatohepatitis), and very high blood triglycerides was found to carry two damaged copies of GPD1, a deletion inherited from the father and a missense change (p.R229Q) inherited from the mother. A liver biopsy showed that GPD1 protein was completely absent.

Additional cases have since expanded the picture. The pattern of inheritance is recessive, meaning a child generally needs two damaged copies to develop the disease. Carrying a single variant typically does not produce overt illness, but it can matter for family planning if a partner also carries a GPD1 variant.

Heart Rhythm and Sudden Cardiac Risk

GPD1L variants tell a different story, focused on the heart. In a study of sudden infant death syndrome (SIDS) and sudden unexplained death cases, researchers identified three rare missense GPD1L mutations (E83K, I124V, and R273C). All three sat at evolutionarily conserved positions in the protein and were absent from 600 reference alleles (300 control subjects), suggesting they were not benign background variation.

In a large multigenerational family with Brugada syndrome (an inherited rhythm disorder that can cause sudden cardiac arrest), a GPD1L variant called A280V was the only rare coding change in the genetic region linked to the disease. In laboratory experiments, this variant reduced the peak sodium current flowing through heart muscle cells by roughly half when coexpressed with SCN5A, a pattern consistent with the loss-of-function sodium channel diseases that underlie Brugada syndrome.

One important nuance: in the Brugada family, GPD1L-A280V appeared alongside common risk variants in the sodium channel genes SCN5A and SCN10A. Affected family members carried more of these background risk alleles than unaffected relatives, suggesting that the GPD1L variant raises risk most when combined with other genetic factors. A single rare variant is rarely the whole story.

Reconciling the Two Pictures

It can be confusing that GPD1 (with GPD1L as its close relative) shows up in both a rare infant liver disease and an adult heart rhythm disorder. These are not the same condition, and they involve different variants in different (though related) genes. GPD1 biallelic loss disrupts liver fat metabolism. GPD1L missense variants alter cardiac sodium currents. Carrying a variant relevant to one system does not automatically mean risk for the other.

Penetrance and What a Variant Actually Means for You

Carrying a risk variant does not guarantee you will develop the associated disease. Genetic researchers use the word penetrance to describe how often a variant actually produces the condition in the people who carry it. For the GPD1L variants linked to Brugada syndrome, penetrance appears to depend heavily on the rest of your genetic background, particularly variants in sodium channel genes. For GPD1 liver disease, the recessive pattern means a single inherited copy typically does not cause illness on its own.

One-Time Test, Lifetime Use

This is a germline DNA test. The result you get today is the result you would get a decade from now. There is no trend to track, no follow-up reading to interpret. The value of the test comes from integrating the result into the rest of your medical decisions for the rest of your life.

If you carry a clinically significant GPD1 or GPD1L variant, the cadence of action shifts to the phenotypes the variants influence. For GPD1L variants linked to cardiac rhythm risk, that may mean periodic ECGs, attention to medications that affect sodium channels, and discussion of any unexplained fainting episodes. For GPD1 carriers planning a pregnancy, that may mean offering carrier testing to a partner. The genotype itself does not need to be re-checked.

Decision Pathway for an Unexpected Result

If your result identifies a known pathogenic or likely pathogenic variant, the most useful next steps are usually three: confirm the variant with a different method if it was called from a SNP chip rather than direct sequencing, involve a genetic counselor or relevant specialist (cardiologist for GPD1L findings, hepatologist or metabolic specialist for GPD1 findings), and discuss testing with biological relatives who share part of your DNA.

If the result is a variant of uncertain significance (a change in the DNA sequence whose clinical meaning has not been firmly established), the appropriate response is usually watchful waiting rather than aggressive intervention. These variants can sometimes be reclassified as more data accumulate. A genetics professional can help you understand where your specific variant sits in the current evidence base.

When Results Can Be Misleading

• Variant panel coverage: the assay detects only the specific GPD1 and GPD1L variants it was designed to find. A result that does not flag a known risk variant does not rule out other rare changes elsewhere in either gene.
• Variants of uncertain significance: an unexpected sequence change may be reported with unclear clinical meaning. These should not be treated as actionable risk findings until the evidence catches up.
• Ethnic-specific allele frequencies: the published evidence for GPD1L variants in Brugada syndrome comes largely from specific family pedigrees and small case series. Risk estimates from one population may not transfer cleanly to another.
• Clinical-grade versus consumer testing: results from a direct-to-consumer genotyping service should usually be confirmed by clinical sequencing before they drive medical decisions, especially for rare variants.